Reminder: The pictures displayed on this site maybe different from the actual appearance of the product,their maybe a delay in updating the recent picture if their a newly launched packaging from the manufacturer
Myhepall is used to treat chronic hepatitis C virus (HCV) infection. Sofosbuvir + Velpatasvir is a drug that combines two antiviral medications.
Velpatasvir and Sofosbuvir
Please negotiate the logistics method with customer service, customer service Whatsapp/Wechat
Please follow the doctor’s advice when taking medicines. The mall only guarantees the quality of the medicines and does not provide medical advice.
Myhepall operate by reducing hepatitis C virus levels in the body and eliminating the virus from the blood over time. Sofosbuvir-velpatasvir is a single-pill combination of pangenotypic NS5A-NS5B inhibitors that has potent action against HCV genotypes 1, 2, 3, 4, 5, and 6. It gives patients with HCV genotype 3 infection, particularly those with compensated cirrhosis, a much-needed choice. Except in conjunction with a third agent, sofosbuvir-velpatasvir has not been examined for any of the genotypes for an abbreviated duration of 8 weeks (voxilaprevir). Acid-reducing medications, particularly proton-pump inhibitors, may have dramatically lowered levels of sofosbuvir-velpatasvir, similar to ledipasvir-sofosbuvir.
One tablet (400 mg sofosbuvir and 100 mg velpatasvir) taken orally once a day with or without food is the suggested dosage for adults.